Your Messages Inbox
Your Article Summary
See Latest ArticlesArzerra (ofatumumab) maa accepted by emea
Genmab, 02/27/09
Genmab A/S announced that the European Medicines Agency has confirmed the Marketing Authorization Application for Arzerra for the treatment of chronic lymphocytic leukemia is valid and that the review procedure started on February 2009. If approved, ofatumumab would be indicated for the treatment of patients with CLL who have previously failed, or are inappropriate for, standard therapies. The MAA was submitted on February 2009.
Today in Marketing/Media/ROI...keeping you current
Receive free subspecialty "5-minute updates" via email
Go Go Generics
PharmExec, 12/18/09
Almirall and Forest Laboratories to Expand Respiratory Collaboration with LAS100977
Forest Laboratories, 12/18/09
Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 2010
Cell Therapeutics, 12/18/09
Article Search
Sponsor